Sign in
4

Changes in Ownership

Beam Therapeutics Inc. Filed Acc 0001193125-26-424421

CEO sold 50,000 shares at an average $23.77 ($1,188,745)

  • CEO acquired 50,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Evans John M. · CEO

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-10-15 Exercise or conversion : show line 1 in the form 10b5-1 +25,000 $1.03 $25,750 1,072,205 D
2026-10-15 Sale : show line 2 in the form 10b5-1 −25,000 $23.57 $589,150 1,047,205 D
2026-10-16 Exercise or conversion : show line 3 in the form 10b5-1 +25,000 $1.03 $25,750 1,072,205 D
2026-10-16 Sale : show line 4 in the form 10b5-1 −25,000 $23.98 $599,595 1,047,205 D
Open-market sales · 50,000 sh · avg $23.77 · $1,188,745

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-10-15 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) −25,000 180,804 D
2026-10-16 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) −25,000 155,804 D
Loading xslF345X06/ownership.xml…